Treatment History Characteristics Associated With Use of Isocarboxazid: A Nationwide Register-Based Study.

Autor: Holm M, Larsen JK, Ishtiak-Ahmed K, Speed M, Gasse C, Østergaard SD

Publikováno v: Journal of clinical psychopharmacology [J Clin Psychopharmacol] 2022 Mar-Apr 01; Vol. 42 (2), pp. 154-158.

The prescriber's guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression.

Autor: Van den Eynde V; PsychoTropical Research, QLD, Australia., Abdelmoemin WR; Department of Psychiatry, University of Toronto, Toronto, ON, Canada., Abraham MM; Neurawell Therapeutics, Boca Raton, FL, USA., Amsterdam JD; Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Anderson IM; Department of Psychiatry, University of Manchester, Manchester, UK., Andrade C; Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore, India., Baker GB; Department of Psychiatry, University of Alberta, Edmonton, AB, Canada., Beekman ATF; Department of Psychiatry, Amsterdam University Medical Center, Amsterdam, The Netherlands., Berk M; Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, VIC, Australia., Birkenhäger TK; Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands., Blackwell BB; Department of Psychiatry, University of Wisconsin, Milwaukee, WI, USA., Blier P; Departments of Psychiatry and Cellular & Molecular Medicine, University of Ottawa, Ottawa, ON, Canada., Blom MBJ; Parnassia Groep, The Hague, The Netherlands., Bodkin AJ; Department of Psychiatry, Harvard Medical School, Boston, MA, USA., Cattaneo CI; Brain Stimulation Italia, Cavaglietto, Italy., Dantz B; Department of Psychiatry and Behavioral Sciences, Rush Medical College, Chicago, IL, USA., Davidson J; Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA., Dunlop BW; Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA, USA., Estévez RF; College of Medicine, University of Central Florida, Orlando, FL, USA., Feinberg SS; Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, New York, NY, USA., Finberg JPM; Department of Molecular Pharmacology, Technion-Israel Institute of Technology, Haifa, Israel., Fochtmann LJ; Department of Psychiatry, Department of Pharmacological Sciences, and Biomedical Informatics, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, USA., Gotlib D; Unaffiliated, Toronto, ON, Canada., Holt A; Department of Psychiatry, University of Alberta, Edmonton, AB, Canada., Insel TR; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, USA., Larsen JK; Department of Affective Disorders, Aarhus University Hospital, Aarhus, Denmark., Mago R; Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Menkes DB; Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand., Meyer JM; Department of Psychiatry, UC San Diego School of Medicine, San Diego, CA, USA., Nutt DJ; Department of Brain Sciences, Imperial College, London, UK., Parker G; Discipline of Psychiatry and Mental Health, University of New South Wales, Sydney, NSW, Australia., Rego MD; Yale Institute for Global Health, Yale School of Medicine, New Haven, CT, USA., Richelson E; Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, FL, USA., Ruhé HG; Department of Psychiatry, Radboud University Medical Center, Nijmegen, The Netherlands., Sáiz-Ruiz J; Department of Psychiatry, Alcala University, Madrid, Spain., Stahl SM; Department of Psychiatry and Neuroscience, University of California, Riverside, Riverside, CA, USA., Steele T; Department of Psychiatry and Behavioral Sciences, University of South Carolina, Columbia, SC, USA., Thase ME; Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Ulrich S; Aristo Pharma GmbH, Berlin, Germany., van Balkom AJLM; Department of Psychiatry, Amsterdam University Medical Center, Amsterdam, The Netherlands., Vieta E; Department of Psychiatry and Psychology, University of Barcelona Hospital Clinic, Barcelona, Spain., Whyte I; Department of Clinical Toxicology and Pharmacology, University of Newcastle, Callaghan, NSW, Australia., Young AH; Department of Psychological Medicine, King's College London, London, UK., Gillman PK; PsychoTropical Research, QLD, Australia.

Publikováno v: CNS spectrums [CNS Spectr] 2023 Aug; Vol. 28 (4), pp. 427-440. Date of Electronic Publication: 2022 Jul 15.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Comparative Examination of Moclobemide, Tranylcypromine, Phenelzine and Isocarboxazid for Monoamine Oxidase–A Inhibition

Autor: Mahmoud Mirzaei, Zahra S. Alidoosti

Publikováno v: Advanced Journal of Chemistry, Section B. 1:23-28

The ligand–receptor complex formations between the monoamine oxidase–A (MAO–A) enzyme and its known inhibitors have been examined based on the in silico approach. The conformational structure of each ligand including moclobemide, tranylcypromin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cdef59f4920294fac2d456b10b1e0450
https://doi.org/10.33945/sami/ajcb.2019.1.5

Response to "Sertraline and isocarboxazid cause a serotonin syndrome".

Autor: Kirrane R, Bodner R, Lynch T

Publikováno v: Journal of clinical psychopharmacology [J Clin Psychopharmacol] 1995 Apr; Vol. 15 (2), pp. 144.